SEC Filing Summary: Cerulean Pharma Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Cerulean Pharma Inc. on March 10, 2016. The report addresses operational highlights for the fourth quarter and the full year ended December 31, 2015, along with anticipated corporate and clinical milestones for 2016. The filing incorporates a press release (Exhibit 99.1) by reference.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the referenced press release (Exhibit 99.1), which is not included in the provided source text.
Material Changes
The document does not explicitly detail material changes versus prior periods in the text provided. It serves as a notification that operational highlights and financial results for the period ended December 31, 2015, have been announced via a separate press release.
Guidance, Outlook, and Risks
Management has announced anticipated corporate and clinical milestones for 2016. The filing includes a standard disclaimer stating that the information provided under Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the specific financial results for Q4 and full-year 2015 by reviewing the attached press release (Exhibit 99.1).
- Confirm the details of the anticipated 2016 clinical milestones referenced in the press release.
- Note that the financial data in this 8-K is not legally "filed" under Section 18 of the Exchange Act.
- Check for any subsequent filings that may update the 2016 outlook or operational status.